Updates from the Miami Breast Cancer Symposium
Read More
Negative PARP inhibitor trial raises questions and dampens hope
Chemotherapy shortage: A symptom of a bigger problem
Why is the San Antonio Breast Cancer Symposium so unique and special?
A disquieting moment: Two steps backwards?
Combining HER2 drugs: Does it work?
Balancing the benefits and risks of hormonal therapy for early-stage breast cancer
Supportive care: An update from San Antonio
Finding the Perfect Prevention Drug
Is a new anti-angiogenic strategy on the horizon?
ODAC's decision on Avastin in breast cancer raises many questions
Sentinel nodes: A convergence of knowledge from different trials
New information from sentinel lymph node studies in breast cancer
ASCO Update: New frontiers in personalized medicine--the Human Genome
DCIS: An example of why screening and disease classification go hand-in-hand
The ordinary drug that could
The evolving story of estrogen replacement and its effects
Preventing breast cancer: What's next?
Health care reform -- Is there a Top 10 list?
Aspirin -- The Drug of the Day
Quality Assurance: How can you make sure you are not a victim of error?
San Antonio Breast Cancer Symposium: What have we learned and where are we going?
Updates on treatment for HER2-positive breast cancer
The importance of cellular pathways and updates on anti-angiogenic drugs
Bisphosphonates and breast cancer risk
New insights on hormonal therapies
What to expect in 2009 at SABCS
Mammographic screening: More heat than light
A general pullback on cancer screening?
A report from the 2009 ASCO Breast Cancer Symposium